{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:16:45Z","timestamp":1791908205353,"version":"4.3.4"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Bayer Hispania SL"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To evaluate the effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction (HFrEF) following recent decompensation in routine clinical practice in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>VERISEC is a prospective, multicentre registry of 835 consecutive patients initiating vericiguat at 41 centres in Spain. Functional class, biochemical markers, ventricular function, and clinical events were analysed during a 1-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Patients (age 71.3 years [SD: 11.2], 78.9% male) received highly optimized baseline therapy: 91.5% SGLT2i, 90.7% beta-blockers, 85.4% RAASi, and 79.8% MRAs. Quadruple therapy remained stable (61.7% baseline to 63.0% at 12 months; P = .526). At 1-year follow-up, significant improvements were observed. NT-proBNP decreased from 3532.0 (IQR: 1689.3\u20136974.5) to 2291.5\u2005pg\/ml (IQR: 1063.0\u20135076.3; P &amp;lt; .001) and LVEF increased from 30.3% (SD: 7.6) to 35.4% (SD: 11.1; P &amp;lt; .001). NYHA class improved, with class II patients increasing from 55.6% to 62.2% (P &amp;lt; .001). Mean HF decompensations requiring intravenous diuretics decreased from 1.34 (SD: 1.1) in the preceding year to 0.65 (SD: 1.3) during follow-up. Non-HF cardiovascular hospitalizations decreased from 0.98 (SD: 1.4) to 0.39 (SD: 1.0). Vericiguat was discontinued in 13.4% of patients, primarily due to symptomatic hypotension (49.4%). Higher baseline NT-proBNP (per 1000-pg\/ml increase) independently predicted discontinuation (OR: 1.06; 95% CI: 1.03\u20131.08; P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Vericiguat added to optimized quadruple therapy was associated with reverse remodelling, reduced NT-proBNP, improved functional class, and a numerical reduction in HF-related events in real-world HFrEF patients. These findings confirm the clinical utility and safety of vericiguat in routine practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag138","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T12:27:27Z","timestamp":1778675247000},"source":"Crossref","is-referenced-by-count":1,"title":["One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3839-7336","authenticated-orcid":false,"given":"Alberto","family":"Esteban-Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Cardiology Department, Hospital Universitario Severo Ochoa , Calle Orellana s\/n, Legan\u00e9s, Madrid 28911 ,","place":["Spain"]},{"name":"Facultad de Ciencias Biom\u00e9dicas y de la Salud, Universidad Alfonso X El Sabio , Avenida Universidad, 1, 28691 Villanueva de la Ca\u00f1ada, Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Calvo-Bernal","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Puerto Real , C\u00e1diz ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9696-2313","authenticated-orcid":false,"given":"Raquel","family":"L\u00f3pez-Vilella","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari La Fe , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"de Lara","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de Torrevieja , Alicante ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia C","family":"Belarte-Tornero","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital del Mar , Barcelona ,","place":["Spain"]},{"name":"Heart Diseases Biomedical Research Group (GREC), IMIM (Hospital del Mar Medical Research Institute) , Barcelona ,","place":["Spain"]},{"name":"Department of Medicine, School of Medicine, Universidad Autonoma de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Barrantes-Castillo","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de Palam\u00f3s , Girona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"G\u00f3mez-Otero","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico de Santiago de Compostela , A Coru\u00f1a ,","place":["Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV) , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Nu\u00f1ez-Villota","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednico de Valencia , Valencia ,","place":["Spain"]},{"name":"Institute of Health Research-INCLIVA , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Robles-Gamboa","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de Toledo , Toledo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"L\u00f3pez-Aguilera","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Reina Sof\u00eda , C\u00f3rdoba ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Torremocha-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario La Paz , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Melendo-Viu","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario \u00c1lvaro Cunqueiro , Vigo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Sim\u00f3n-Ram\u00f3n","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Sant Pau , Barcelona ,","place":["Spain"]},{"name":"Institut de Recerca Sant Pau , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Fluvi\u00e0-Burgu\u00e9s","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Dr Trueta , Girona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J","family":"Pastor-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Virgen de la Arrixaca , Murcia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Alonso-Salinas","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario de Navarra , Pamplona ,","place":["Spain"]},{"name":"Navarrabiomed, Instituto de Investigaci\u00f3n en Salud (IdISNa) , Pamplona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Garc\u00eda-Pinilla","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV) , Madrid ,","place":["Spain"]},{"name":"Cardiology Department, Hospital Universitario Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]},{"name":"IBIMA-Plataforma BIONAND , M\u00e1laga ,","place":["Spain"]},{"name":"Departamento de Medicina y Dermatolog\u00eda, Universidad de M\u00e1laga , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Pomares-Var\u00f3","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitari Mutua Terrassa , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jara","family":"Gay\u00e1n-Ord\u00e1s","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Arnau de Vilanova de Lleida , Lleida ,","place":["Spain"]},{"name":"Institut de Recerca Biom\u00e8dica de Lleida , Lleida ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gonz\u00e1lez-Calle","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario de Salamanca , Salamanca ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"D\u00edez-Villanueva","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital La Princesa , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Galv\u00e1n-Ruiz","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Dr Negrin , Las Palmas ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Ortiz-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Fundaci\u00f3n de Alcorc\u00f3n , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Caravaca-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Clinic de Barcelona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Goena-Vives","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Donostia , San Sebasti\u00e1n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Seller","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital de Denia , Alicante ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Jim\u00e9nez-Blanco","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Cardiovascular (CIBERCV) , Madrid ,","place":["Spain"]},{"name":"Cardiology Department, Hospital Universitario Ram\u00f3n y Cajal , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Codina","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Germans Trias I Pujol , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Vietiez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Lucus Augusti, Lugo , Lugo ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Jord\u00e1n-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Virgen de las Nieves , Granada ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Thiscal","family":"L\u00f3pez-Lluva","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Universitario de Le\u00f3n , Le\u00f3n ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Mena-Sebasti\u00e0","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Mois\u00e9s Broggi , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"P\u00e1jaro","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Juan Ram\u00f3n Jim\u00e9nez , Huelva ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Recio-Mayoral","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Virgen Macarena , Sevilla ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"VERISEC investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Camacho","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel Iniesta","family":"Manjavacas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mirabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia L\u00f3pez","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis Bonilla","family":"Palomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cobo-Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Corredera","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Escolar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"G\u00f3rriz-Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ainara","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Olivella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther S\u00e1nchez","family":"Corral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikel","family":"Taibo-Urqu\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Berm\u00fadez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Mart\u00ednez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026060809164673200_xvag138-B1","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026060809164673200_xvag138-B2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41569-024-01046-6","article-title":"Global epidemiology of heart failure","volume":"21","author":"Khan","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2026060809164673200_xvag138-B3","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.rec.2022.08.009","article-title":"Age and stabilization of admissions for heart failure in Spain (2006\u20132019). The beginning of the end of the \u201cepidemic\u201d?","volume":"76","author":"Anguita G\u00e1mez","year":"2023","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2026060809164673200_xvag138-B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2025.102571","article-title":"Expanded definition of worsening heart failure: impact on clinical outcomes and quality-of-life assessment","volume":"13","author":"Chaudhary","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026060809164673200_xvag138-B5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.amjcard.2022.08.035","article-title":"Impact of worsening heart failure on long-term prognosis in patients with heart failure with reduced ejection fraction","volume":"184","author":"Chimed","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026060809164673200_xvag138-B6","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10741-025-10497-z","article-title":"Worsening heart failure: progress, pitfalls, and perspectives","volume":"30","author":"Fonseca","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026060809164673200_xvag138-B7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026060809164673200_xvag138-B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"2026060809164673200_xvag138-B9","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"key":"2026060809164673200_xvag138-B10","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s00392-023-02241-0","article-title":"Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction","volume":"113","author":"Esteban-Fern\u00e1ndez","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026060809164673200_xvag138-B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1504427","article-title":"Clinical profile of an unselected population with heart failure treated with vericiguat in real life: differences with the VICTORIA trial","volume":"11","author":"Esteban-Fern\u00e1ndez","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"2026060809164673200_xvag138-B12","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in patients with heart failure and reduced ejection fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N Engl J Med"},{"key":"2026060809164673200_xvag138-B13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026060809164673200_xvag138-B14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.rceng.2025.02.006","article-title":"VERICIDuAT: real-life study of vericiguat in patients with heart failure with reduced ejection fraction","volume":"225","author":"Russo Botero","year":"2025","journal-title":"Rev Clin Esp (Barc)"},{"key":"2026060809164673200_xvag138-B15","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1002\/ehf2.15032","article-title":"Clinical profile, associated events and safety of vericiguat in a real-world cohort: the VERITA study","volume":"11","author":"Galv\u00e1n Ruiz","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026060809164673200_xvag138-B16","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2024-10-5","article-title":"Vericiguat in patients with heart failure and implantable cardioverter-defibrillator","volume":"14","author":"Escobar","year":"2025","journal-title":"Drugs Context"},{"key":"2026060809164673200_xvag138-B17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113222","article-title":"Vericiguat use in patients with heart failure in real-world settings during the first year after the drug authorization in Japan","volume":"13","author":"Okami","year":"2024","journal-title":"J Clin Med"},{"key":"2026060809164673200_xvag138-B18","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1536\/ihj.24-091","article-title":"Who can receive clinical benefit from mid-term vericiguat add-on therapy among patients with systolic heart failure receiving quadruple medical therapy?","volume":"65","author":"Imamura","year":"2024","journal-title":"Int Heart J"},{"key":"2026060809164673200_xvag138-B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134396","article-title":"Initial experience of vericiguat treatment in patients with heart failure and reduced ejection fraction","volume":"12","author":"Nakamura","year":"2023","journal-title":"J Clin Med"},{"key":"2026060809164673200_xvag138-B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132524","article-title":"Vericiguat in heart failure with reduced ejection fraction patients on guideline-directed medical therapy: insights from a 6-month real-world study","volume":"417","author":"Tian","year":"2024","journal-title":"Int J Cardiol"},{"key":"2026060809164673200_xvag138-B21","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2024.1476976","article-title":"Vericiguat combined with \u201cnew quadruple\u201d therapy enhances cardiac function and life quality in patients with heart failure: a single-center prospective study","volume":"11","author":"Zhao","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2026060809164673200_xvag138-B22","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2512427","article-title":"Characterizing vericiguat treatment in heart failure: a multicenter real-world study in China","volume":"25","author":"Wang","year":"2024","journal-title":"Rev Cardiovasc Med"},{"key":"2026060809164673200_xvag138-B23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12872-025-04477-2","article-title":"Efficacy of vericiguat in patients with chronic heart failure and reduced ejection fraction: a prospective observational study","volume":"25","author":"Zhan","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"key":"2026060809164673200_xvag138-B24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00228-024-03654-0","article-title":"Real-world characteristics and use patterns of patients treated with vericiguat: a nationwide longitudinal cohort study in Germany","volume":"80","author":"Kerwagen","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"2026060809164673200_xvag138-B25","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1714\/4551.45503","article-title":"Real-world experience with early use of vericiguat in worsening heart failure","volume":"26","author":"Scelsi","year":"2025","journal-title":"G Ital Cardiol (Rome)"},{"key":"2026060809164673200_xvag138-B26","doi-asserted-by":"publisher","DOI":"10.31083\/RCM39886","article-title":"The role of vericiguat in heart failure therapy: from clinical trials to clinical practice","volume":"26","author":"Tricarico","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"2026060809164673200_xvag138-B27","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.121.009337","article-title":"Vericiguat and health-related quality of life in patients with heart failure with reduced ejection fraction: insights from the VICTORIA trial","volume":"15","author":"Butler","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026060809164673200_xvag138-B28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.17925\/HI.2022.16.2.112","article-title":"Natriuretic peptide-guided therapy for heart failure","volume":"16","author":"Horiuchi","year":"2022","journal-title":"Heart Int"},{"key":"2026060809164673200_xvag138-B29","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jchf.2020.08.008","article-title":"N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study","volume":"8","author":"Ezekowitz","year":"2020","journal-title":"JACC Heart Fail"},{"key":"2026060809164673200_xvag138-B30","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1002\/ehf2.14050","article-title":"Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial","volume":"9","author":"Senni","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026060809164673200_xvag138-B31","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1628411","article-title":"Initiation of vericiguat and short-term cardiovascular function improvement in heart failure patients with and without worsened renal function","volume":"12","author":"Zhang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"2026060809164673200_xvag138-B32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1253\/circrep.CR-24-0076","article-title":"Effect of vericiguat on left ventricular reverse remodeling in patients who have heart failure with reduced ejection fraction\u2014special focus on patients without quadruple medical therapy","volume":"6","author":"Fujii","year":"2024","journal-title":"Circ Rep"},{"key":"2026060809164673200_xvag138-B33","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ejhf.2836","article-title":"Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: the VICTORIA echocardiographic substudy","volume":"25","author":"Pieske","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026060809164673200_xvag138-B34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(25)01665-4","article-title":"Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"406","author":"Butler","year":"2025","journal-title":"Lancet"},{"key":"2026060809164673200_xvag138-B35","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/s00392-025-02663-y","article-title":"Tachycardia-induced cardiomyopathy in de novo heart failure: prevalence, short-term outcomes, and the role of guideline-directed therapy in ejection fraction improvement","volume":"115","author":"Esteban-Fern\u00e1ndez","year":"2025","journal-title":"Clin Res Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag138\/68281601\/xvag138.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag138\/68281601\/xvag138.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag138\/68281601\/xvag138.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:16:54Z","timestamp":1780924614000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag138\/8677720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag138","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,5]]},"article-number":"xvag138"}}